60687-347 : Mesalamine 800 mg Oral Tablet, Delayed Release


NDC: 60687-347
Labeler: American Health Packaging
Product Type: Human Prescription Drug
Drug Name:  Mesalamine
Dosage Form: Oral Tablet, Delayed Release
Application #: NDA021830
Rev. Date: 


Appearance:


Markings: WC;800
Shapes:  Capsule
Colors:  Brown
Size (mm): 19
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

WC 800: (60687-347) Mesalamine 800 mg Oral Tablet, Delayed Release by American Health Packaging
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 60687-347-25: 30 BLISTER PACK IN 1 BOX, UNIT‑DOSE (60687‑347‑25) > 1 TABLET, DELAYED RELEASE IN 1 BLISTER PACK (60687‑347‑95)

Active Ingredients:

  • Mesalamine

Dosage Strength:

  • 800 mg

Inactive Ingredients:

  • Silicon Dioxide
  • Dibutyl Sebacate
  • Ferric Oxide Red
  • Ferric Oxide Yellow
  • Lactose Monohydrate
  • Magnesium Stearate
  • Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)
  • Methacrylic Acid - Methyl Methacrylate Copolymer (1:1)
  • Polyethylene Glycol, Unspecified
  • Povidone, Unspecified
  • Sodium Starch Glycolate Type a Potato
  • Talc

Pharmaceutical Classes:

  • Aminosalicylate [EPC]
  • Aminosalicylic Acids [CS]

Related Products:

Based on records with the same trade name.
  • 60687-264 Mesalamine 800 mg Oral Tablet, Delayed Release by American Health Packaging
  • 60687-397 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by American Health Packaging
  • 60687-408 Mesalamine 800 mg Oral Tablet, Delayed Release by American Health Packaging
  • 60687-556 Mesalamine 400 mg Oral Capsule, Delayed Release by American Health Packaging
  • 60687-650 Mesalamine .375 g/1 Oral Capsule, Extended Release by American Health Packaging
  • 60687-703 Mesalamine 500 mg Oral Capsule, Extended Release by American Health Packaging
  • 0093-5907 Mesalamine 400 mg Oral Capsule, Delayed Release by Teva Pharmaceuticals USA, Inc.
  • 0093-9224 Mesalamine 375 mg Oral Capsule, Extended Release by Teva Pharmaceuticals USA, Inc.-
  • 0378-1375 Mesalamine .375 g/1 Oral Capsule, Extended Release by Mylan Pharmaceuticals Inc.
  • 0378-7401 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Mylan Pharmaceuticals Inc.
  • 0378-9230 Mesalamine 1000 mg Rectal Suppository by Mylan Pharmaceuticals Inc.
  • 0472-1915 Mesalamine 1000 mg Rectal Suppository by Actavis Pharma, Inc.
  • 0527-3012 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Lannett Company Inc.
  • 0591-2245 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Actavis Pharma, Inc.
  • 0781-7088 Mesalamine 1000 mg Rectal Suppository by Sandoz Inc
  • 0832-6056 Mesalamine .375 g/1 Oral Capsule, Extended Release by Upsher-smith Laboratories, LLC
  • 0904-6832 Mesalamine 800 mg Oral Tablet, Delayed Release by Major Pharmaceuticals
  • 16714-245 Mesalamine 1000 mg Rectal Suppository by Northstar Rx LLC.
  • 16714-830 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Northstar Rx LLC.
  • 21922-045 Mesalamine 4 g/60ml Rectal Suspension by Encube Ethicals Private Limited
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 60687-347 QR Code

< Prev: 60687-346Next: 60687-349 >

Related Discussions:

Will PENTASA (mesalamine) contradict diabetes medications
I am taking PENTASA (mesalamine) 500 mg tablets daily (6 tabs daily) and I also use azoran 5 mg two tabs daily. Will it ...
Cheap Purchase of Mesalamine Enemas
I am interested in self-employment. I have Ulcerative Colitis. I need this medication to stay alive. My doctor tells me ... 1 reply
Asacol (mesalamine) delayed-release tablet
mesalamine delayed-release tablet information...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.